Literature DB >> 12358724

Antiproliferative action of valproate is associated with aberrant expression and nuclear translocation of cyclin D3 during the C6 glioma G1 phase.

Christopher L Bacon1, Helen C Gallagher, John C Haughey, Ciaran M Regan.   

Abstract

Cell cycle progression is tightly regulated by cyclins, cyclin-dependent kinases (cdks) and related inhibitory phophatases. Here, we employed mitotic selection to synchronize the C6 glioma cell cycle at the start of the G1 phase and mapped the temporal regulation of selected cyclins, cdks and inhibitory proteins throughout the 12 h of G1 by immunoblot analysis. The D-type cyclins, D3 and D1, were differentially expressed during the C6 glioma G1 phase. Cyclin D1 was up-regulated in the mid-G1 phase (4-6 h) while cyclin D3 expression emerged only in late G1 (9-12 h). The influence of the anticonvulsant agent valproic acid (VPA) on expression of cyclins and related proteins was determined, since its teratogenic potency has been linked to cell cycle arrest in the mid-G1 phase. Exposure of C6 glioma to VPA induced a marked up-regulation of cyclin D3 and decreased expression of the proliferating cell nuclear antigen. In synchronized cell populations, increased expression of cyclin D3 by VPA was detected in the mid-G1 phase (3-5 h). Immunocytochemical localization demonstrated rapid intracellular translocation of cyclin D3 to the nucleus following VPA exposure, suggesting that VPA-induced cell cycle arrest may be mediated by precocious activation of cyclin D3 in the G1 phase.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12358724     DOI: 10.1046/j.1471-4159.2002.01081.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

Review 1.  Epigenetic therapy of leukemia: An update.

Authors:  Nitin Jain; Adriana Rossi; Guillermo Garcia-Manero
Journal:  Int J Biochem Cell Biol       Date:  2008-10-17       Impact factor: 5.085

2.  Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo.

Authors:  Amine Achachi; Arnaud Florins; Nicolas Gillet; Christophe Debacq; Patrice Urbain; Germain Manfouo Foutsop; Fabian Vandermeers; Agnieszka Jasik; Michal Reichert; Pierre Kerkhofs; Laurence Lagneaux; Arsène Burny; Richard Kettmann; Luc Willems
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-08       Impact factor: 11.205

3.  Interpreting clinical assays for histone deacetylase inhibitors.

Authors:  Nadine Martinet; Philippe Bertrand
Journal:  Cancer Manag Res       Date:  2011-05-09       Impact factor: 3.989

4.  Valproate inhibits MAP kinase signalling and cell cycle progression in S. cerevisiae.

Authors:  Kristelle Desfossés-Baron; Ian Hammond-Martel; Antoine Simoneau; Adnane Sellam; Stephen Roberts; Hugo Wurtele
Journal:  Sci Rep       Date:  2016-10-26       Impact factor: 4.379

5.  The role and possible molecular mechanism of valproic acid in the growth of MCF-7 breast cancer cells.

Authors:  Xiao-Jie Ma; Yun-Shan Wang; Wei-Ping Gu; Xia Zhao
Journal:  Croat Med J       Date:  2017-10-31       Impact factor: 1.351

6.  Valproic acid induces differentiation and inhibition of proliferation in neural progenitor cells via the beta-catenin-Ras-ERK-p21Cip/WAF1 pathway.

Authors:  Gyung-Ah Jung; Ju-Yong Yoon; Byoung-San Moon; Dong-Hwa Yang; Hyun-Yi Kim; Sang-Hun Lee; Vitezslav Bryja; Ernest Arenas; Kang-Yell Choi
Journal:  BMC Cell Biol       Date:  2008-12-09       Impact factor: 4.241

7.  O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.

Authors:  Ken Sasai; Tsuyoshi Akagi; Eiko Aoyanagi; Kouichi Tabu; Sadao Kaneko; Shinya Tanaka
Journal:  Mol Cancer       Date:  2007-06-05       Impact factor: 27.401

8.  Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells.

Authors:  Dinesh Thotala; Rowan M Karvas; John A Engelbach; Joel R Garbow; Andrew N Hallahan; Todd A DeWees; Andrei Laszlo; Dennis E Hallahan
Journal:  Oncotarget       Date:  2015-10-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.